• Cumberland Pharmaceuticals announced Phase 2a ASSIST-SSc top-line results on Oct. 23, 2026, showing oral ifetroban was generally well tolerated in systemic sclerosis patients.
• Gastrointestinal and bleeding-related adverse events were more frequent with ifetroban but predominantly mild; no serious adverse events were attributed to treatment.
• The trial was not designed to establish efficacy; limited disease progression and its small size prevented conclusions about treatment benefits.
• Planned biomarker studies and cardiac imaging evaluations will inform decisions on further development in systemic sclerosis.
• The company plans to submit the clinical study report to the U.S. Food and Drug Administration.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cumberland Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610231605PR_NEWS_USPR_____CL80110) on October 23, 2026, and is solely responsible for the information contained therein.